Janciauskiene Sabina, Wrenger Sabine, Günzel Steffen, Gründing Anna Ricarda, Golpon Heiko, Welte Tobias
Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Front Oncol. 2021 Feb 19;11:622076. doi: 10.3389/fonc.2021.622076. eCollection 2021.
An association between acute-phase proteins (APPs) and cancer has long been established and there are numerous reports correlating altered levels and/or molecular forms of APPs with different types of cancers. Many authors have shown a positive correlation between high levels of APPs, like alpha1-antitrypsin (AAT), and unfavorable clinical outcome in cancers. Conversely, others proposed that high levels of APPs are probably just a part of nonspecific inflammatory response to cancer development. However, this might not be always true, because many cancerous cells produce or take up exogenous APPs. What is the biological significance of this and what benefit do cancer cells have from these proteins remains largely unknown. Recent data revealed that some APPs, including AAT, are able to enhance cancer cell resistance against anticancer drug-induced apoptosis and autophagy. In this review, we specifically discuss our own findings and controversies in the literature regarding the role of AAT in cancer.
急性期蛋白（APPs）与癌症之间的关联早已确立，并且有许多报告将APPs水平改变和/或分子形式与不同类型的癌症联系起来。许多作者已经表明，高水平的APPs，如α1-抗胰蛋白酶（AAT），与癌症患者不良临床结局呈正相关。相反，其他人则提出，高水平的APPs可能只是对癌症发展的非特异性炎症反应的一部分。然而，情况可能并非总是如此，因为许多癌细胞会产生或摄取外源性APPs。这其中的生物学意义是什么，癌细胞从这些蛋白质中获得了什么益处，在很大程度上仍然未知。最近的数据显示，一些APPs，包括AAT，能够增强癌细胞对抗癌药物诱导的凋亡和自噬的抗性。在这篇综述中，我们专门讨论了我们自己的研究发现以及文献中关于AAT在癌症中的作用的争议。
